License agreement: Photoswitch Biosciences develops drug discovery technology using optogenetics
Channelrhodopsins, first isolated by Max Planck researchers from the green algae Chlamydomonas reiinhardii in 2002, have been successfully used both in vitro and in vivo to control and study a variety of critical bioelectrical systems. Now the US company, Photoswitch Biosciences Incorporated, is developing a complete assay system specifically designed to leverage the advantages of channelrhodopsin-based optical control in drug screening and safety pharmacology studies. Genetically-engineered cell lines or stem cell derived models combined with voltage sensitive dyes and a first in class microplate reader allow unprecedented throughput and economy in assaying models of nerve and heart cell function.
The new instrumentation platform was developed partly on the basis of a non-exclusive license agreement with Max Planck Innovation, the technology transfer organization of the Max Planck Society, for the use of biological photoreceptors for the direct control of light activated ion channels.
About Max Planck Innovation
Max Planck Innovation is responsible for the technology transfer of the Max Planck Society and, as such, the link between industry and basic research. With our interdisciplinary team we advise and support scientists of the Max Planck Institutes in evaluating their inventions, filing patents and founding companies. We offer industry a unique access to the innovations of the Max Planck Institutes. Thus, we perform an important task: the transfer of basic research results into products, which contribute to the economic and social progress.
Diplom-Kaufmann, certified graphic designer
Phone: +49 89 / 29 09 19-30